LinkoCare is a knowledge-intensive private limited company registered and operating in Sweden with the primary mission of commercialization of bioengineered corneal implants to help restore sight to millions of people around the world suffering from corneal blindness, low vision, and refractive error such as presbyopia. The company’s mandate is to establish itself as a world leader in the field of bioengineered products and a knowledge hub for R&D. LinkoCare’s long-term goal is to provide the vision, strategy, and management capability for further development and commercialization of bioengineered medical devices platforms. LinkoCare is currently building next generation bioengineered corneas and refractive devices for sight restoration and correction. Our company has been successful in the European Innovation space. For instance, our associated company, NaturaLens AB, won the first prize in the EIT-Health (European Innovation & Technology Institute Wild Card).
LinkoCare’s innovative and patented technology platform involves treating vision loss due to corneal blindness, low vision, and refractive error through collagen-based intra-corneal implants that are made of biocompatible material (100% natural materials) and mimic the human cornea while having superior optical properties, reproducibility, cost-effectiveness, and quality than the human cornea and devices made from human cornea and synthetic materials. It has a long shelf life (minimum 2 years), a 0% rejection rate for implantation (Rafat et al., Nature Biotechnology NBT-RA54039D [2022]), is less expensive than existing solutions (2x less than human cornea, human cornea lenticles, and synthetic implants and inlays) and require a minimally invasive, relatively affordable implantation procedure (<€1000) with a quick recovery period (1 month and a light drug regimen). The first product, named CorVision inlay, is highly customizable and is desined to manage myopia. It has already been approved by a European Regulatory Authurity and successfully tested in 110 patients in Eurpe with 6-12 months post-op follow up data.